BUSINESS CONCEPT
Patent protected drug candidates based on new mode of actions showing promising results in preclinical studies.
STRATEGY
Arcede aims at being an attractive partner for academic research groups, biotech companies and global pharmaceutical companies with expertise positioned all along the drug development path – from academic research to finished product on the market.
VISION
Aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients.
COLLABORATIONS with strategic partners
who assume the financial and operational responsibility for developing the final product.
ARCEDE Pharma – Project Portfolio
RCD405
The drug candidate (RCD405) for the treatment of COPD and severe asthma in preclinical phase, belonging to the RESP9000 project. Additional undisclosed preclinical assets.
